To investigate the health-related quality of life (HRQoL) of patients receiving allogeneic hematopoietic SCT (allo-HSCT) from HLA-haploidentical/partially matched related donors (HID/PMRD) and to compare this value with that of patients receiving allo-HSCT from HLA-identical sibling donor (ISD), a total of 350 patients receiving allo-HSCT were enrolled in a study (ISD: 173; HID/PMRD: 177). HRQoL post transplantation was evaluated by an SF-36 questionnaire. The effect of various factors on the HRQoL was analyzed through COX regression. Compared with the ISD group, patients in the HID/PMRD group had higher scores in physical functioning, general health, bodily pain, vitality and emotional role functioning, and these patients functioned significantly better on the physical and mental component summaries. Also, long-term survivors exhibit better HRQoL. Measured by multivariate analysis, extensive chronic GVHD was observed to have a strongly negative impact on patients' HRQoL, while male gender status, lower age when receiving allo-HSCT and returning to work or school were associated with positive impacts on at least one subscale. These results showed that the HRQoL of patients receiving HID/PMRD hematopoietic SCT (HSCT) is comparable to that of patients receiving ISD HSCT, and HLA disparity is not the factor affecting the HRQoL.
INTRODUCTION
Allogeneic hematopoietic SCT (allo-HSCT) is an effective option and is sometimes the only treatment for hematological malignancies. A healthy sibling donor with identical HLA is preferred but is unavailable for many patients. In recent years, increasing numbers of patients with hematological disease have benefited from HLA-haploidentical/partially matched related allo-HSCT. Transplantation without in vitro T-cell depletion is applied at our institute 1, 2 and has achieved 2-year leukemia-free survival of 68.2% in standard-risk patients and of 42.1% in high-risk patients. 1 Hematopoietic SCT aims not only for disease-free survival but also for recovery to normal life and work. It is, therefore, inappropriate to evaluate the transplantation efficacy based purely on survival rate and time. Health-related quality of life (HRQoL) should be considered to be an important index for evaluating the efficacy of allo-HSCT.
Numerous studies have previously investigated factors affecting the HRQoL in patients treated with HLA-identical related and unrelated allo-HSCT. Chronic GVHD (cGVHD) was the most adverse factor. 3 --5 The follow-up time since transplantation also had a positive crucial role in the HRQoL, and the HRQoL returned fully to normal within 3 --5 years. 6 --11 Other studies indicated that the age at transplantation, 7, 12, 13 acute GVHD, 7 histocompatibility of the donor 7 and work/study status 8, 12 were related to HRQoL. However, there are relatively few studies on the factors affecting the HRQoL in patients treated with HLA-haploidentical/partially matched related allo-HSCT.
In this study, the HRQoL of patients receiving allo-HSCT from HLA-haploidentical/partially matched related donor (HID/PMRD) was investigated and was compared with that of patients receiving allo-HSCT from HLA-identical sibling donors (ISD). We sought to determine whether histocompatibility of the donor affected the HRQoL of patients surviving long after transplantation.
MATERIALS AND METHODS Patients
Before beginning, the study protocol was approved by the Ethics Committee of Peking University People's Hospital. Patients receiving allo-HSCT from either HID/PMRD (n ¼ 481) or ISD (n ¼ 381) between January 2005 and December 2008 were eligible if they were X24 months post hematopoietic SCT (HSCT) and in continued CR since HSCT. Patients who had mental disease, such as depression or psychosis before HSCT, were excluded. A total of 254 patients died (HID/PMRD group: n ¼ 161, ISD group: n ¼ 93), and 14 relapsed (HID/PMRD group: n ¼ 8, ISD group: n ¼ 6). Of the remaining 594 survivors, 188 (31.6%) could not be contacted by phone, and 56 (9.5%) refused to participate. Ultimately, 350 (58.9%) patients agreed to participate, and they were enrolled in the study (HID/ PMRD group: n ¼ 177, ISD group: n ¼ 173). Characteristics of the patients are summarized in Table 1 .
Donor selection
A HLA-matched sibling donor was the first choice for allo-HSCT. If a matched sibling donor was unavailable as a first-treatment option, patients without a suitable closely HLA-matched unrelated donor, that is, with more than 8 of 10 matching HLA-A, B, C, DR and DQ loci and at least 5 of 6 matching HLA-A, B and DR loci, or whose disease status left insufficient time for an unrelated donor search, were eligible for HLA-haploidentical/partially matched related allo-HSCT. To determine HLA-A and HLA-B status, lowresolution DNA techniques were used. High-resolution techniques were used for HLA-DRB1 typing. All donor --recipient pairs were typed at the HLA-A, B and DR loci at our institute. Each patient with a partially matched related donor received stem cells from a family member who shared one HLA haplotype with the patient but differed to a variable degree for the HLA-A, B and D Ags of the haplotype not shared. Apart from each donor --recipient pair, HLA typing was performed for parents and offspring to be strictly analyzed to guarantee true haploid genetic background. The HLA disparities in the mismatched cohort are shown in Table 1 .
Transplantation regimen
Preconditioning consisted of cytarabine (À10 to À9 days), BU (4 mg/kg per day, À8 to À6 days), CY (1.8 g/m 2 per day, À5 to À4 days) and simustine (Me-CCNU, 250 mg/m 2 , À3 days). Furthermore, cytarabine was administered at 4 g/m 2 per day along with anti-thymocyte globulin (ATG; 2.5 mg/kg, À5 to À2 days) in patients receiving HLA-haploidentical allo-HSCT 1,2 and at 2 g/m 2 per day (not in combination with ATG) in patients with HLA-identical allo-HSCT. The prevention regimen for acute GVHD was CsA þ short-course MTX þ mycophenolate mofetil. CsA was begun at 1.25 mg/kg on day À9 before transplantation, being administered as an i.v. drip at an interval of 12 h followed by a switch to oral administration after gastrointestinal function returned to normal, and the trough concentration was adjusted to 150 --250 ng/mL. Mycophenolate mofetil was initiated at 500 mg twice daily on day À9 and was titrated slowly downward until day þ 30 and discontinued on day þ 60 in patients with HLA-haploidentical allo-HSCT; the treatment was withdrawn after graft survival in patients receiving HLA-identical allo-HSCT. Standard-risk patients were defined as patients in the first or second CR (CR1 or CR2) of AML, ALL or non-Hodgkin's lymphoma in the first chronic phase (CP1) of CML or severe aplastic anemia. The other patients were classified as highrisk patients. GVHD was diagnosed and graded in accordance with the common international criteria. 14, 15 Assessment of quality of life
The Mos 36-Item Short-Form Health Survey (SF-36) is a widely used HRQoL measure for adults, including physical functioning (PF), role-PF, bodily pain, general health, vitality (VT, measuring the subjective feeling of energy and fatigue degree), social functioning, role-emotional functioning (RE) and mental health, and subscales are aggregated to form two summary measures: the physical component summary and mental component summary with a population mean of 50 and a standard deviation of 10; higher scores indicate better functioning. 16 This survey's Chinese version is well-validated. 17 For the Chinese version of the SF-36, a 'strongly recovered' result for a particular subscale was defined as displaying a score higher than the mean score for that subscale.
Study procedure
Disease-free survivors who received allo-HSCT from 2005 to 2008 at our institute were contacted by phone by the investigators, who informed the survivors of the purpose of the study. A package that included a consent form, a set of questionnaires and a self-addressed stamped envelope were mailed to the patients willing to participate. All patients were requested to sign written informed-consent forms, complete questionnaires and return them at their earliest convenience. Patients' detailed clinical information was gathered through transplant program database.
Statistical analysis
The w 2 test and Student's t-test were used to compare demography, disease and treatment-related factors, as well as SF-36 scores between patients treated with ISD and HID/PMRD HSCT. COX regression analysis was used to identify the factors that may affect HRQoL. Unless otherwise specified, all of the reported P-values were based on two-sided hypothesis tests. Data analyses were conducted with the SPSS software package (SPSS Inc., Chicago, IL, USA).
RESULTS

SF-36 scores
More than 60% of patients reported strong recovery in the mental health, VT, PF and general health subscales, with ratios of 86.3%, 82.0%, 66.9% and 65.1%, respectively, being observed. Patients treated with HID/PMRD HSCT functioned comparable or better on HRQoL, which was indicated by comparable or higher scores ( Table 2 ).
The effect of time from transplantation on HRQoL We used 48 months as the dividing point for the analysis of follow-up time, as it was the mean follow-up after allo-HSCT for the patients of this study. HRQoL of patients surviving more than 48 months was superior to that of patients surviving less than 48 months after transplantation, which was indicated by higher scores, although there were no statistically significant differences in the general health, VT, role-emotional functioning and mental component summary subscales (Table 3) .
Effects of demography, disease and treatment-related factors on HRQoL Factors affecting HRQoL after transplantation were categorized as pre-HSCT factors (age at transplantation, gender, marital status, diagnosis, disease status and HLA disparity), HSCT-related factors (acute GVHD and cGVHD) and a post HSCT factor (work/study status). In univariate analysis, extensive cGVHD adversely affected all eight subscales, and returning to work/school positively affected seven subscales, except bodily pain; these two factors both showed significant impact on physical component summary and mental component summary. In addition, the following factors affected at least one subscale: gender (bodily pain, role-PF, mental health and social functioning); age at transplantation (role-PF, and social functioning); HLA disparity (PF, and VT) and marital status (VT). Factors with significant differences found in univariate analysis were subjected to multivariate analysis. Extensive cGVHD was still the most significantly adverse factor affecting HRQoL; lower age at allo-HSCT, male sex and returning to work/school were associated with positive impact on at least one subscale. HLA disparity lost its significance and was eliminated from the final multivariate analysis (Table 4) .
Of the 200 patients suffering from cGVHD, 121 of them (60.5%) reported skin involvement, while lung, liver, gastrointestinal tract and eye involvement showed mostly negative influences on HRQoL.
Analysis of non-respondents Demography, disease and treatment-related factors were compared between respondents and non-respondents. The results indicated that the proportion of patients suffering from cGVHD was lower in non-respondents (50.0 vs 16.0%, P ¼ 0.000); other factors did not differ significantly between the groups.
Reasons for refusing to participate in the study A total of 56 patients refused to participate in the study. Eighteen (32.1%) did not provide definite reasons and only replied, 'Do not want to participate in the study'; the remaining 38 patients offered clear reasons, including 32 (84.2%) patients who recovered well but did not choose to participate in the study (25: 'Would not like to recall disease-related events'; 4: 'Too busy to finish the questionnaire'; and 3: 'Could not receive the letter due to outside work/study commitments'); only 6 (15.8%) patients refused to participate because 'post transplantation complications led to poor quality of life.' DISCUSSION Although many studies had evaluated the HRQoL of patients after allo-HSCT, 6 --13,18,19 to the best of our knowledge, the present study was the first comparative trial concerning HRQoL between patients receiving HID/PMRD HSCT and ISD HSCT. Many studies have suggested that 25 --93%, 10 --13,18 63 --77% 10,13 and 84% 19 of those who received HLA-identical-related or -unrelated HSCT exhibited strong recovery in terms of general health, physical health and mental health, respectively. These values are similar to those found in our study: 65.1%, 66.9% and 86.3%, respectively. HRQoL of patients receiving HID/PMRD HSCT was comparable to those who receiving ISD HSCT, as indicated by comparable or even higher scores in subscales and component scores of SF-36; it is therefore suggested that in our transplantation system, HRQoL was desirable in patients treated with HID/PMRD HSCT.
In multivariant analysis of this study, factors affecting HRQoL after HID/PMRD HSCT primarily consisted of extensive cGVHD, age at transplantation, gender and work/study status after transplantation, and extensive cGVHD is the most adverse factor affecting HRQoL after transplantation, as in previous studies. 3, 5, 10, 12, 13, 20 Several scholars indicated that use of mismatched or unrelated donors was a risk factor for cGVHD. 20 However, Teshima et al.
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only noted a tendency for increasing cGVHD with increasing HLA disparity, rather than a statistically significant correlation (P ¼ 0.05); other studies found that the occurrence of cGVHD did not differ between patients receiving ISD vs HID/PMRD HSCT, 22, 23 which may be due to the usage of ATG in these studies. Several studies observed that the incidence of cGVHD and extensive cGVHD decreased sharply (23 --40% and 23 --26%, respectively) in patients treated with ATG compared with patients treated without ATG. 24 --26 For HID/PMRD HSCT, as performed in this study, T-cell depletion mediated by ATG was one of the key methods in immunological tolerance induction. The ratio of cGVHD and extensive cGVHD of the HID/PMRD group was 44.1% and 26.3%, respectively, which was significantly lower than that of ISD group in this study (cGVHD: 44.1% vs 74.2%, P ¼ 0.000; extensive cGVHD: 26.3% vs 46.0%, P ¼ 0.006), and was similar to our previous report (cGVHD: 44.6%, extensive cGVHD: 23.3% respectively), 1 confirming that the induction of immunological tolerance with ATG effectively decreased the incidence of cGVHD and extensive cGVHD in patients receiving HID/PMRD HSCT. Therefore, HRQoL after HID/PMRD HSCT was comparable to that after ISD HSCT.
Younger patients may have been more likely to have had acute leukemia and therefore been sicker and/or received more chemotherapy before transplant. These patients are also more likely to receive HID/PMRD HSCT and may account for the younger age of patients having a lower HRQoL. But some studies also demonstrated that younger patients had better HRQoL after HSCT; 7, 12, 13 HRQoL recovery was especially superior in patients younger than 25 years. 11, 12 In this study, the mean age at transplantation of patients with HID/PMRD HSCT was 30.7±11.4 years, which is significantly younger than patients with ISD HSCT, and the proportion of patients who were younger than 25 years in the HID/PMRD group was significantly higher than that of patients in ISD group (37.9% vs 6.4%, P ¼ 0.000). But multivariate analysis revealed that age at transplantation affected only one subscale (role functioning-physical), illustrating that age difference might have had limited effects on HRQoL of patients in this study, but the effect of age to the HRQoL still could not be excluded.
The greatest disadvantage in this study is that a large proportion of patients did not reply to our invitation. A 60% response rate is low but is not unreasonable for these crosssectional studies. This low response rate may be related to our failure to offer a reward and to the design of the postal questionnaire, which is acknowledged to yield a low response rate. 27 --29 Furthermore, certain patients might be not willing to take part in the study, because of poor recovery of HRQoL. To decrease this bias to the greatest extent possible, we compared the demography, disease and treatment-related factors of respondents with those of non-respondents, and the results showed that cGVHD developed less frequently in non-respondents. In this study, we observed that cGVHD is the most adverse factor affecting HRQoL, and a lower incidence of cGVHD suggested that HRQoL of non-respondents may be at least not poorer than respondents. Furthermore, the analysis of known refusal reasons found that up to 85% of patients refused to take part in the study, although they had strong recovery of HRQoL, illustrating those non-respondents may have comparable HRQoL to respondents. Another disadvantage of this study is that retrospective HRQoL assessments suffered from recall bias; this phenomenon may be overcome by performing further perspective studies.
In conclusion, the HRQoL in patients receiving HID/PMRD HSCT is comparable to that of patients receiving ISD HSCT. Time elapsed since allo-HSCT had a significant influence on HRQoL, and extensive cGVHD is the most adverse factor affecting HRQoL, but HLA disparity is not a factor affecting the HRQoL. This study is the first to show that patients receiving HID/PMRD HSCT can gain desirable HRQoL. However, this result should be supported further by a multicenter and large-scale study.
